# Mannkind Corporation clinical trials: 57 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 57 trials with Mannkind Corporation as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Mannkind Corporation: 57 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/mannkind-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 57
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 57, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 1, 2026 | NCT07679893 | Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis | Mannkind Corporation | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679893) |
| January 15, 2026 | NCT07344558 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis | Mannkind Corporation | Phase 1 | Completed | Idiopathic Pulmonary Fibrosis (IPF) | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07344558) |
| November 4, 2025 | NCT07224321 | INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | Mannkind Corporation | Phase 2 | Recruiting | Type 1 Diabetes Mellitus | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224321) |
| August 1, 2024 | NCT06532942 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers | Mannkind Corporation | Phase 1 | Unknown | Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06532942) |
| May 17, 2024 | NCT06418711 | ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension | Mannkind Corporation | Phase 3 | Terminated | MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06418711) |
| June 15, 2023 | NCT05904743 | INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes | Mannkind Corporation | Phase 4 | Completed | Diabetes Mellitus, Type 1 | 141 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05904743) |
| February 17, 2022 | NCT05243628 | Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes | Mannkind Corporation | Phase 4 | Completed | Type 1 Diabetes | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05243628) |
| July 23, 2021 | NCT04974528 | Afrezza® INHALE-1 Study in Pediatrics | Mannkind Corporation | Phase 3 | Completed | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 319 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04974528) |
| April 19, 2021 | NCT04849845 | Afrezza® Dosing Optimization Study | Mannkind Corporation | Phase 4 | Completed | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04849845) |
| March 14, 2018 | NCT03464864 | Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers | Mannkind Corporation | Phase 1 | Completed | Pulmonary Arterial Hypertension | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03464864) |
| August 18, 2015 | NCT02527265 | Afrezza Safety and Pharmacokinetics Study in Pediatric Patients | Mannkind Corporation | Phase 2 | Completed | Type 1 Diabetes Mellitus | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02527265) |
| June 30, 2015 | NCT02485327 | PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1... | Mannkind Corporation | Phase 1 | Completed | Type 1 Diabetes Mellitus | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02485327) |
| June 12, 2015 | NCT02470637 | Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of... | Mannkind Corporation | Phase 1 | Completed | Type 1 Diabetes Mellitus | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02470637) |
| November 13, 2013 | NCT01982604 | Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers | Mannkind Corporation | Phase 1 | Completed | Healthy Volunteers | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01982604) |
| July 18, 2013 | NCT01902121 | Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge | Mannkind Corporation | Phase 1 | Completed | Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01902121) |
| February 26, 2013 | NCT01798914 | Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder | Mannkind Corporation | Not applicable | No longer available | Type 1 Diabetes, Type 2 Diabetes | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01798914) |
| March 6, 2012 | NCT01544881 | Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes | Mannkind Corporation | Phase 1 | Completed | Type 1 Diabetes Mellitus | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01544881) |
| December 13, 2011 | NCT01490762 | Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler | Mannkind Corporation | Phase 1 | Completed | Healthy | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01490762) |
| October 13, 2011 | NCT01451398 | Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus | Mannkind Corporation | Phase 3 | Completed | Type 2 Diabetes | 353 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01451398) |
| October 4, 2011 | NCT01445951 | Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment... | Mannkind Corporation | Phase 3 | Completed | Type 1 Diabetes Mellitus | 518 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01445951) |
| June 3, 2011 | NCT01365117 | Pharmacokinetic Study in Healthy Volunteers | Mannkind Corporation | Phase 1 | Completed | Healthy Volunteers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01365117) |
| September 15, 2010 | NCT01201928 | Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166 | Mannkind Corporation | Observational | Terminated | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01201928) |
| September 8, 2010 | NCT01196104 | Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler | Mannkind Corporation | Phase 3 | Terminated | Type 2 Diabetes | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01196104) |
| December 4, 2009 | NCT01026051 | Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma | Mannkind Corporation | Phase 2 | Terminated | Stage III Melanoma, Stage IV Melanoma | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01026051) |
| November 30, 2009 | NCT01021891 | A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in... | Mannkind Corporation | Phase 1 | Completed | Chronic Obstructive Pulmonary Disease (COPD) | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01021891) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 22 |
| Phase 1/2 | 1 |
| Phase 2 | 14 |
| Phase 3 | 13 |
| Phase 4 | 3 |
| Not applicable | 1 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 45 |
| Terminated | 8 |
| Recruiting | 2 |
| No longer available | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 23 |
| Diabetes Mellitus, Type 1 | 21 |
| Diabetes Mellitus | 9 |
| Insulin Resistance | 7 |
| Melanoma | 5 |
| Respiratory Aspiration | 4 |
| Asthma | 3 |
| Respiratory Tract Infections | 2 |
| Idiopathic Pulmonary Fibrosis | 2 |
| Hyperglycemia | 1 |
| Pulmonary Fibrosis | 1 |
| Fibrosis | 1 |
| Endometrial Neoplasms | 1 |
| Uterine Cervical Neoplasms | 1 |
| Testicular Neoplasms | 1 |
| Thyroid Neoplasms | 1 |
| Small Cell Lung Carcinoma | 1 |
| Mesothelioma | 1 |
| Breast Neoplasms | 1 |
| Esophageal Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Carcinoma, Neuroendocrine | 1 |
| Liver Neoplasms | 1 |
| Gallbladder Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hotels in the United States](https://specstream.ai/data/businesses/hotels/united-states)
- [Tea wholesalers in the United States](https://specstream.ai/data/businesses/tea-wholesalers/united-states)
- [Dumpling restaurants in the United States](https://specstream.ai/data/businesses/dumpling-restaurants/united-states)
- [Pizza restaurants in the United States](https://specstream.ai/data/businesses/pizza-restaurants/united-states)
- [Bearing suppliers in the United States](https://specstream.ai/data/businesses/bearing-suppliers/united-states)
- [Junk removal companies in the United States](https://specstream.ai/data/businesses/junk-removal-companies/united-states)
